Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Hannah Fields, Valentina Ferrari, BA, Alison Tarke, BS, Randy Guo-Shi Tsai, BS, BA, Timothy Luger, Colin McCarthy, BS, Ruifeng Chen, Xinlian Zhang, Thomas A Lane, MD, Antonella Vitiello, Dr. Pharm., Rafael Bejar, MD PhD, Tiffany N Tanaka, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142038

Published: 2020

Journal Articles

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

David A. Sallman, MD, Tracey Iraca, Casey L. O'Connell, MD, Rafael Bejar, MD PhD, Sandra Kurtin, ANP

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134647

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Niroshan Nadarajah, Alex Wagner, PhD, Rafael Bejar, MD PhD, Mark Ewalt, MD, Annette S. Kim, MD, Michelle M. Le Beau, PhD, Xiaotu Ma, PhD, Manja Meggendorfer, PhD, Jamile M. Shammo, MD, Gabriella Ryan, Alexa J. Siddon, MD, David P. Steensma, MD, Matthew J. Walter, MD, Ahmet Zehir, PhD, Jinghui Zhang, PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141204

Published: 2020

Journal Articles

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Soo Park, MD, Brian M Reilly, BS, Timothy Luger, Dan Zhao, Robert J. Fram, MD, Ajeeta B Dash, PhD, Rafael Bejar, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134484

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Alison Tarke, Valentina Ferrari, BA, Hannah Fields, Luca Ferrari, Franco Ferrari, PhD, Tiffany N Tanaka, MD, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2019) 134 (Supplement_1): 4870.

https://doi.org/10.1182/blood-2019-131474

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Blood (2019) 134 (Supplement_1): 4271.

https://doi.org/10.1182/blood-2019-126978

Published: 2019

Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA

Blood (2019) 134 (Supplement_1): 5898.

https://doi.org/10.1182/blood-2019-128517

Published: 2019

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Valentina Ferrari, Tiffany N Tanaka, MD, Alison Tarke, Hanna Fields, Luca Ferrari, Alex Ni, Franco Ferrari, PhD, John Warner, PhD, Theresa Jochelson, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2018) 132 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2018-99-118834

Published: 2018

Journal Articles

Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

Ling Zhang, MD, Donald M Stablein, PhD, Pearlie Epling-Burnette, PhD PharmD, Alexandra M. Harrington, MDMT(ASCP), Lynn C. Moscinski, MD, Steven Kroft, MD, Amy E. DeZern, MD, Tareq Al Baghdadi, MD, Jane Jijun Liu, MD, Matthew J. Walter, MD, Rafael Bejar, MD PhD, Edward J. Gorak, DO, MBA, MS, Rami S. Komrokji, MD, Gregory A. Abel, MD MPH, Bart L Scott, MD, Steven D. Gore, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4370.

https://doi.org/10.1182/blood-2018-99-116629

Published: 2018

Journal Articles

DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS

Brian M Reilly, BS, Tiffany N Tanaka, MD, Dinh Diep, PhD, Huwate Yeerna, BS, Pablo Tamayo, PhD, Kun Zhang, PhD, Rafael Bejar, MD PhD

Blood (2018) 132 (Supplement 1): 106.

https://doi.org/10.1182/blood-2018-99-111535

Published: 2018

Journal Articles

Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

Jill A Bell, PhD, Farrah A Pompilus, Anna Christian, MPH, Flora Mazerolle, MSc, Fatima Scipione, Rafael Bejar, MD PhD, Aaron Galaznik, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Stefan Cano, PhD CPsychol, AFBPsS, Antoine Regnault, PhD

Blood (2018) 132 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2018-99-116977

Published: 2018

Journal Articles

Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice

Samuel A Stoner, Ming Yan, PhD, Katherine Liu, Takahiro Shima, MD PhD, Huan-You Wang, MD PhD, Kei-Ichiro Arimoto, PhD, Rafael Bejar, MD PhD, Catriona Jamieson, MD PhD, Kun-Liang Guan, PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 99.

https://doi.org/10.1182/blood-2018-99-115591

Published: 2018

Journal Articles

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Alexander B Pine, MD PhD, Nora B Chokr, MD, Maximilian Stahl, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Mark R. Litzow, MD, Selina Luger, MD, Richard M. Stone, MD, Peter L Greenberg, MD, Rafael Bejar, MD PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS

Blood (2018) 132 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2018-99-113888

Published: 2018

Journal Articles

Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis

Blood (2017) 130 (Supplement 1): 3457.

https://doi.org/10.1182/blood.V130.Suppl_1.3457.3457

Published: 2017

Journal Articles

Germline Tissues and DNA Sequencing Analysis Methods for Optimal Somatic Variant Detection in Myelodysplastic Syndrome (MDS)

Eric Padron, MD, Jamie Teer, PhD, Markus Christian Ball, PhD, Jeffrey S Painter, BS, Rami S. Komrokji, MD, Ling Zhang, MD, Lynn C. Moscinski, MD, Mikkael A. Sekeres, MD MS, Steven D. Gore, MD, Rafael Bejar, MD PhD, Matthew J. Walter, MD, Pearlie Epling-Burnette, PhD PharmD

Blood (2017) 130 (Supplement 1): 1685.

https://doi.org/10.1182/blood.V130.Suppl_1.1685.1685

Published: 2017

NARROW

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS

Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank

Germline Tissues and DNA Sequencing Analysis Methods for Optimal Somatic Variant Detection in Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only